May 9, 2017

INTERVIEW: Cambria Automobiles Could double or treble earnings over medium term – Zeus

Cambria Automobiles plc (LON:CAMB), the franchised motor retailer is the topic of conversation when Mike Allen, Head of Research at Zeus Capital caught up with DirectorsTalk to discuss the latest..

European Metals Holdings Ltd Q&A: Granting of Permits & PFS Study (LON:EMH)

European Metals Holdings Ltd (LON:EMH) Managing Director Keith Coughlan caught up with DirectorsTalk for an exclusive interview to discuss the granting of three key permits for the Cinovec project and..

Vipera Plc Q&A with Chief Executive Officer Marco Casartelli: Significant Contract Win

Vipera Plc (LON:VIP) Chief Executive Officer Marco Casartelli caught up with DirectorsTalk for an exclusive interview to discuss their preliminary results, their significant contract win and how they’re progressing in..

RedstoneConnect plc Acquisition of Anders + Kern U.K. Limited

RedstoneConnect Plc (LON:REDS), a leading provider of technology and services for smart buildings and commercial spaces, has today announced that it has entered into a conditional agreement to acquire the..

Cambria Automobiles Plc H1 PBT +5% ahead, +21.7% YOY

Cambria Automobiles Plc (LON:CAMB) delivered strong H1 results with adjusted PBT exceeding our forecast by 5.1% and delivering growth of 21.7% YOY. Softer vehicle volumes were offset by a significant..

Blue Star Capital Investment update on Stahler

Blue Star Capital Plc (LON:BLU) have today announced that one of its investee companies Sthaler Limited (“Sthaler”) has successfully raised £3million at a pre-new money valuation of £20 million. This..

CentralNic Group plc FY16 in line, strategy focussed on acquisitions, driving recurring earnings

FY16 results show that CentralNic Group Plc (LON:CNIC) has delivered revenue of £22.1m (+113%), adj. EBITDA of £5.5m (+68%) and adj. PBT of £4.7m (+60%), in line with market expectations..

OptiBiotix Health Plc Non-Exclusive European License Agreement with Nutrilinea

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it has agreed to grant a non-exclusive license..

Search

Funds

May 9, 2017

Search

Funds

May 9, 2017

FTSE 100

Funds